Home Newsfeeds Jones Lang LaSalle Sets Long-Term Growth Strategy

Jones Lang LaSalle Sets Long-Term Growth Strategy

Real estate and investment management firm Jones Lang LaSalle Inc (NYSE:JLL) expects 2025 Fee revenue to be $10 billion – $11 billion.…

byShivani Kumaresan

November 16, 2022

1 minute read

Real estate and investment management firm Jones Lang LaSalle Inc (NYSE:JLL) expects 2025 Fee revenue to be $10 billion – $11 billion.
It sees 2025 adjusted EBITDA margin of 16% – 19%.
In addition, JLL is currently expecting to operate within a Net Debt to Adjusted EBITDA leverage range of 0.0x to 2.0x.
“The commercial real estate industry is being shaped by the rapid adoption of technology and an increased focus on sustainability,” said CEO Christian Ulbrich.
Price Action: JLL shares traded higher by 3.15% at $165.74 on the last check Wednesday.

Future Of GM Autonomous Vehicle Maker Cruise In Peril After 900 Job Cuts

By Neil Dennis

December 14, 4:05 PM

Layoffs follow suspension of operating license in California for GM's Cruise division after accident.

DRIV

News

Lifezone Metals Announces Completion of Funding for Phase 1 Platinum, Palladium and Rhodium Recycling Joint Venture with Glencore

By Benzinga Newsdesk

January 10, 7:05 AM

Lifezone Metals Limited's (NYSE:LZM) Chief Executive Officer, Chris Showalter, is pleased to announce the signing of the Subscription Agreement and completion of funding for Phase 1 of the joint

LZM

Legal
News

Fortuna Receives Positive Decision From Mexican Court Which Reinstates The San Jose Mine Environmental Impact Authorization

By Benzinga Newsdesk

Yesterday, 5:13 AM

Fortuna Silver Mines Inc. (NYSE:FSM) (TSX:FVI) reports that the Mexican Federal Administrative Court (the "Court") has ruled in favour of Minera Cuzcatlan, Fortuna's Mexican subsidiary, and re-instated

FSM

Vertex Announces Approval Of First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY, For The Treatment Of Sickle Cell Disease And Transfusion-Dependent Beta Thalassemia In Kingdom Of Saudi Arabia

By Benzinga Newsdesk

January 9, 1:44 PM

- CASGEVY™ is first medicine ever to be evaluated through the SFDA's Breakthrough Medicines Program -- First treatment center in Saudi Arabia has been activated -Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

VRTX

Jones Lang LaSalle Sets Long-Term Growth Strategy

Related Posts

Future Of GM Autonomous Vehicle Maker Cruise In Peril After 900 Job Cuts

Lifezone Metals Announces Completion of Funding for Phase 1 Platinum, Palladium and Rhodium Recycling Joint Venture with Glencore

Fortuna Receives Positive Decision From Mexican Court Which Reinstates The San Jose Mine Environmental Impact Authorization

Vertex Announces Approval Of First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY, For The Treatment Of Sickle Cell Disease And Transfusion-Dependent Beta Thalassemia In Kingdom Of Saudi Arabia